Atricure 

$27.98
12
+$0.00+0% Tuesday 20:00

統計

當日最高
28.85
當日最低
27.59
52週高點
43.18
52週低點
25.36
成交量
675,617
平均成交量
-
市值
1.39B
本益比
-
股息殖利率
-
股息
-

即將到來

財報

4Aug預期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
下一步
-0.33
-0.21
-0.08
0.04
預期EPS
-0.00625
實際EPS
不適用

財務

-2.14%利潤率
未盈利
2020
2021
2022
2023
2024
2025
1.07B營收
-22.9M淨利

分析師評級

52.20平均目標價
最高預估為 55.00。
來自過去6個月內的 6 則評分。這不是投資建議。
買入
67%
持有
33%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 ATRC 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Show more...
執行長
Mr. Michael H. Carrel
員工
1300
國家
美國
ISIN
US04963C2098

上市

0 Comments

分享你的想法

FAQ

Atricure 今天的股價是多少?
ATRC 目前價格為 $27.98 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Atricure 股價表現。
Atricure 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Atricure 的股票以代號 ATRC 進行交易。
Atricure 的股價在上漲嗎?
ATRC 股票較上週上漲 +1.71%,本月下跌 -0.5%,過去一年 Atricure 下跌 -14.17%。
Atricure 的市值是多少?
今天 Atricure 的市值為 1.39B
Atricure 下一次財報日期是什麼時候?
Atricure 將於 August 04, 2026 公布下一次財報。
Atricure 上一季度的財報如何?
ATRC 上一季度的財報為每股 0 USD,預估為 -0.06 USD,帶來 +100% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Atricure 去年的營收是多少?
Atricure 去年的營收為 1.07BUSD。
Atricure 去年的淨利是多少?
ATRC 去年的淨收益為 -22.9MUSD。
Atricure 有多少名員工?
截至 June 17, 2026,公司共有 1,300 名員工。
Atricure 位於哪個產業?
Atricure從事於Health & Wellness產業。
Atricure 何時完成拆股?
Atricure 最近沒有進行任何拆股。
Atricure 的總部在哪裡?
Atricure 的總部位於 美國 的 Mason。